Sun Pharmaceutical Industries Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is CANAGLIFLOZIN, with a corresponding US DMF Number 31290.
Remarkably, this DMF maintains an Active status since its submission on March 18, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 18, 2017, and payment made on January 05, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II